INTRODUCTION {#SEC1}
============

The DNA base cytosine can exist in a variety of modified forms of which 5-methylcytosine (mC) is the most abundant in vertebrates ([@B1]). Cytosine methylation is implicated in regulation of a variety of molecular processes, including transcription and chromosome organization ([@B2]). In most cell types cytosine modification occurs almost exclusively at the dinucleotide CG, but in brain the dinucleotide CA is also highly methylated particularly within the trinucleotide CAC ([@B3],[@B4]). The 5-methylcytosine binding protein MeCP2 is also present at high levels in neuronal cells ([@B5]) where it interacts with both methyl-CG (mCG) and methyl-CAC (mCAC) ([@B6]). A primary function of MeCP2 is to recruit the NCoR1/2 corepressor complex to these methylated sites and thereby restrain neuronal transcription ([@B6],[@B8]). Mutations compromising either DNA binding or corepressor recruitment cause the severe neurological disorder Rett syndrome, emphasizing the importance of this role ([@B9],[@B11]). Discrete protein domains responsible for methyl-CpG/mCAC binding (the methyl-binding domain: MBD) and NCoR1/2 interaction domain (NID) have been defined by deletion analysis and X-ray crystallography of the protein--DNA and protein--protein complexes ([@B9],[@B12]). Importantly, these two domains alone are sufficient to rescue survival of MeCP2-deficient mice ([@B15]).

Most studies confirm the pivotal importance of DNA methylation in determining the MeCP2 interaction with chromatin ([@B5],[@B7],[@B8],[@B16],[@B17]), but evidence that other features of DNA sequence can be recognized has been presented (see ([@B18])). These findings question the notion that MeCP2 is predominantly a 'reader' of the epigenetic DNA methylation mark. If non-methylated sites were to be prominent among its targets, MeCP2 could be viewed less as a reader of the epigenome, which varies in different developmental cell lineages, and more of a conventional transcription factor that interprets the unchanging DNA sequence. Thus, interpretation of MeCP2 function is strongly affected by whether it is instructed by the epigenome alone or also by the genomic base sequence. To investigate the significance of DNA methylation-independent binding, we chose to re-visit the best-characterized example of a specific non-methylated DNA sequence that is targeted by MeCP2. Early *in vitro* experiments established that an N-terminal fragment of chicken MeCP2 bound with high affinity to several DNA sequences that typically contained a GT-rich sequence, often flanked by an A/T-run ([@B19],[@B20]). Recently a structure of the MeCP2 MBD in complex with GTG(T)-containing DNA has been solved ([@B21]). Using human MeCP2 we defined GT-rich sequences that can interact with domains of MeCP2 and showed that binding depends on guanine and the pyrimidine methyl group provided by thymine. Unexpectedly, the full-length protein failed to exhibit detectable DNA methylation-independent binding *in vitro*, suggesting that this may be a property only of MeCP2 sub-fragments. We therefore tested MeCP2 binding to GT-rich motifs *in vivo*. Using independent assays based on chromatin immunoprecipitation-sequencing (ChIP-seq) and transposase accessible chromatin sequencing (ATAC-seq), we were unable to detect this mode of MeCP2 binding, even when MeCP2 was expressed at high levels. These results suggest that GT-rich binding is an *in vitro* phenomenon that is not relevant *in vivo*. They therefore strengthen the likelihood that symmetrically methylated mCG and asymmetrically methylated mCAC are the primary recognition modules for MeCP2 in living cells.

MATERIALS AND METHODS {#SEC2}
=====================

Recombinant MeCP2 expression and purification {#SEC2-1}
---------------------------------------------

Recombinant human MeCP2 protein was fused to a C-terminal histidine tag, to facilitate purification, and expressed from the vector pET30b. Plasmids expressing MeCP2\[1-205\]; MeCP2\[77-167\]; and MeCP2\[1-486\] were constructed as described previously ([@B29]). Proteins were produced in bacteria using standard procedures as described ([@B22]) (see Figure [1A](#F1){ref-type="fig"}).

![MeCP2 \[1--205\] binds to non-methylated GT-rich DNA *in vitro* and requires a methyl group provided by thymine. (**A**) Coomassie stained gel of purified recombinant proteins used in this study, full-length MeCP2\[1--486\], MeCP2\[1--205\] and MeCP2\[77--167\]. M = protein standard (Precision Plus, Bio-Rad). (**B**) Schematic diagram of the fragments of MeCP2 used here and in earlier studies. The lower diagrams show fragments of chicken MeCP2 tested previously for binding to GT-rich sequences (MAR) with high affinity, indicating whether GT binding was detected ([@B20]). The human MBD (grey shading) is located between amino-acids 78 and 162 ([@B14]). The highly homologous chicken MBD (also grey) extends from amino-acid 79 to 163. (**C**) EMSAs using varying amounts of MeCP2\[1--205\] or no protein (−) with probes containing non-methylated CG (CG), methylated CG (mCG), methylated CAC (mCAC) or GGTGT. (**D**) Graph showing quantification of MeCP2\[1--205\] binding to probes containing CG (filled squares), mCG (filled circles), mCAC (filled triangles) or GGTGT (crosses). Mean percentage of probe shifted (±SEM) based on triplicate experiments. (**E**) EMSAs using no protein (−) or varying amounts of MeCP2\[1--205\] with probes containing GGTGT, GGUGU, GGUGT or GGTGU to assess the influence of the thymine methyl group on binding.](gkaa102fig1){#F1}

Oligonucleotide probes {#SEC2-2}
----------------------

Synthetic DNA oligonucleotides (Biomers, Germany) were based on a 58 bp parent probe derived from promoter III of the mouse *Bdnf* locus whose crystal structure in conjunction with MeCP2\[77-167\] has been solved ([@B12]). The sequence contains a central mCG motif followed at the 3′-end by an A/T-flank. In some experiments, the CG or A/T-flank were substituted with the sequences indicated in Table [1](#tbl1){ref-type="table"}. Single-stranded oligonucleotides were annealed and end-labelled with T4 polynucleotide kinase (NEB) and ^32^P-γ-ATP (Perkin Elmer). For pull-down assays the parent DNA sequences were as described in ([@B23]) with the adjustments described in Table [1](#tbl1){ref-type="table"}.

###### 

Oligonucleotides used in this study

  Name                        Sequence of oligonucleotide
  --------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CG (parent)                 5′-AAGCATGCAATGCCCTGGAA**CGG**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  mCG                         5′-AAGCATGCAATGCCCTGGAA**mCGG**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  CAC                         5′-AAGCATGCAATGCCCTGGAA**CAC**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  mCAC                        5′-AAGCATGCAATGCCCTGGAA**mCAC**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GGTGT                       5′-AAGCATGCAATGCCCTGGAA**GGTGT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GT~1~                       5′-AAGCATGCAATGCCCTGGAA**GT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GT~2~                       5′-AAGCATGCAATGCCCTGGAA**GTGT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GT~3~                       5′-AAGCATGCAATGCCCTGGAA**GTGTGT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GT~4~                       5′-AAGCATGCAATGCCCTGGAA**GTGTGTGT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GT~5~                       5′-AAGCATGCAATGCCCTGGAA**GTGTGTGTGT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  ATGT                        5′-AAGCATGCAATGCCCTGGAA**ATGT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  CTGT                        5′-AAGCATGCAATGCCCTGGAA**CTGT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  TTGT                        5′-AAGCATGCAATGCCCTGGAA**TTGT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GTAT                        5′-AAGCATGCAATGCCCTGGAA**GTAT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GTCT                        5′-AAGCATGCAATGCCCTGGAA**GTCT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GTTT                        5′-AAGCATGCAATGCCCTGGAA**GTTT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GTGA                        5′-AAGCATGCAATGCCCTGGAA**GTGA**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GTGC                        5′-AAGCATGCAATGCCCTGGAA**GTGC**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GTGG                        5′-AAGCATGCAATGCCCTGGAA**GTGG**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GGUGU                       5′-AAGCATGCAATGCCCTGGAA**GGUGU**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GGUGT                       5′-AAGCATGCAATGCCCTGGAA**GGUGT**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GGTGU                       5′-AAGCATGCAATGCCCTGGAA**GGTGU**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GT~2~-inv bot               5′-AAGCATGCAATGCCCTGGAA**ACAC**AATTCTTCTAATAAAAGATGTATCATTTTAAATGC-3′
  GT~2~-A/T mut               5′-AAGCATGCAATGCCCTGGAA**GTGT**AA**CG**CTTCT**CG**TA**CG**AGATGTATCATTTTAAATGC-3′
  CG: pull-down template      5′-ACGTATATACGATTTACGTTATACGATTACGATATACGATTTACGTTAATACGTTTACGATTATTACGAATTTACGTTTTTACGAATATACGAAATACGTTTAATACGTAATTACGTATATTACGTATATACGATTTACGAATTACG-3′
  CAC: pull-down template     5′-GCACATATGCACTTTGCACTATGCACTTGCACTATGCACTTTGCACTAATGCACTTGCACTTATTGCACATTTGCACTTTTGCACATATGCACAATGCACTTAATGCACAATTGCACATATTGCACATATGCACTTTGCACATTGCA-3′
  GTGT: pull-down template    5′-GCACATATGCACTTTGCACTATGCACTTGTGTTATGTGTTTTGTGTTAATGTGTTTGTGTTTATTGTGTATTTGTGTTTTTGTGTATATGTGTAATGTGTTTAATGTGTAATTGTGTATATTGCACATATGCACTTTGCACATTGCA-3′
  GGTGT: pull-down template   5′-GCACATATGCACTTTGCACTATGCACT**GGTGT**TA**GGTGT**TT**GGTGT**TAA**GGTGT**T**GGTG**TTTAT**GGTGT**ATT**GGTGT**TTT**GGTGT**ATA**GGTGT**AA**GGTGT**TTAA**GGTGT**AAT**GGTGT**ATATTGCACATATGCACTTTGCACATTGCA-3′

m = methylated. All molecules were annealed to the appropriate methylated or non-methylated reverse oligonucleotide.

Electrophoretic mobility shift assay {#SEC2-3}
------------------------------------

Labelled DNA probe (1 ng) and 1 μg poly deoxyadenylic-thymidylic acid (polydA-dT) competitor (Sigma-Aldrich) were co-incubated on ice for 30 min with the indicated amount of MeCP2 in a 20 μl reaction volume containing 10 mM Tris--HCl, pH 7.5; 150 mM KCl, 0.1 mg/ml BSA; 5% glycerol; 0.1 mM EDTA. In the case of MeCP2\[1--486\], reactions were performed in 250 mM KCl ([@B24]). Samples were resolved on a chilled 10% TBE-acrylamide gel run at 100 V for 70 min in TBE. Gels were exposed to a phosphor screen overnight and imaged using a Typhoon FLA 9500 scanner (GE Healthcare). Where indicated the amount of probe bound by recombinant MeCP2 was quantified, in triplicate, using ImageJ software.

DNA pull-down assay {#SEC2-4}
-------------------

This assay was essentially as described ([@B23]) with the following modifications. PCR-generated, biotin end-labelled 147 bp DNA probes (2 μg) were coupled to M280-streptavidin Dynabeads according to the manufacturer\'s instructions (Invitrogen). In the case of CG and CAC these motifs were either non-methylated or methylated (see Table [1](#tbl1){ref-type="table"} for sequences). Bead-DNA complexes were then co-incubated with 20 μg of rat brain nuclear protein extract ([@B25]) for 1.5 h at 4°C. Following extensive washing, bead-bound proteins were eluted using Laemmli buffer (Sigma) and resolved on a 4--15% SDS-polyacrylamide gel (NEB). The presence of MeCP2 was assayed by western blot using anti-MeCP2 monoclonal antibody M6818 (Sigma); with secondary detection employing IR-dye secondary antibodies (IRDye 800CW donkey anti-mouse, LI-COR Biosciences) then scanned using a LI-COR Odyssey machine.

Generation of LUHMES cell lines expressing various levels of MeCP2 {#SEC2-5}
------------------------------------------------------------------

The procedure for culture and differentiation of the LUHMES ([Lu]{.ul}nd [H]{.ul}uman [Mes]{.ul}encephallic) cell line was previously described in ([@B26]). LUHMES cells expressing various levels of MeCP2 expression have been described in ([@B10]).

Illumina sequencing and data analysis {#SEC2-6}
-------------------------------------

The ChIP-seq, ATAC-seq and bisulfite mapping were performed as described ([@B10]). The data reported in this paper were deposited in the Gene Expression Omnibus (GEO) database, [www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo) (accession no. GSE125660). Trimmomatic version 0.32 was used to perform quality control on 94 and 75 bp paired-end reads to remove adapter sequence and unreliable reads for both TAB-seq and ChIP-seq. For TAB-seq, we used Bismark version 0.10 to further align and process the reads. Mapping was performed in bowtie2 mode to the human hg19 reference genome. Following alignment, duplicated reads were removed and methylation values were extracted as Bismark coverage and cytosine context files. We calculated the methylation percentage at each cytosine position as (mC/C)x100 and generated \*.bed files for further processing. Bwa mem version 0.7.5 was used to map reads to the human hg19 reference genome. We filtered the alignments to remove reads that map to multiple locations in the genome and to blacklisted regions defined by the ENCODE project. We further removed duplicate reads with Picard version 1.107 MarkDuplicates (<http://broadinstitute.github.io/picard/>). To account for varying read depths we used deepTools version 2.5.1 to create bigWig files normalised by RPKM (reads per kilobase per million reads). To quantify MeCP2 occupancy on the genomic features of interest (mCG, mCA, GT, etc.), we rejected reads longer than 1 kb as alignment artefacts.

ChIP-seq enrichment analysis {#SEC2-7}
----------------------------

We used the EMBOSS tool dreg to find all instances of GT motifs in the hg19 reference sequence with a downstream run of at least two AT dinucleotides within thirteen bases. Overlapping motifs were merged and we selected 50 bases ± the start of each region using BEDTools. The average methylation state and read coverage of each region was calculated using bigWigAverageOverBed in conjunction with the processed BS-seq data. Regions with mean read coverage \<10 were dropped and the remaining regions were subsetted based on the mean methylation percentage of all cytosine (mC%). Non-methylated regions were classified as mC% = 0 while methylated regions were defined as mC% \> 10. We then plotted the relative enrichment of MeCP2 ChIP (WT and OE 11x) versus KO in 100 base bins across methylated and non-methylated regions for each GT motif as well as a set of control motifs (GGGTTT, TTTGGG). The relative enrichment is the log2 ratio of normalised read counts of MeCP2 ChIP versus KO ChIP scaled to the mean of the three flanking bins on either side of the plot. Next, we calculated the local GC% of each region by quantifying average GC% across the 2 kb plotted region. All filtering and plotting were performed in R using the base packages as well as genomation, seqplots and ggplot2.

ATAC-seq footprint analysis {#SEC2-8}
---------------------------

We obtained insertion profiles as described ([@B10]). The positions of insertions were accumulated to create insertion count profiles centred at different genomic features: (i) mCA, (ii) CA, (ii) GTGT, GGTGT (irrespectively of methylation) within 14 bases of a 3′AT-run as described in *Results*. To calculate the relative insertion probability profiles and remove Tn5 bias, we calculated$$\documentclass[12pt]{minimal}
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RESULTS {#SEC3}
=======

Nucleotide determinants of cytosine methylation-independent DNA binding by MeCP2 {#SEC3-1}
--------------------------------------------------------------------------------

To investigate the molecular basis of MeCP2 binding to non-methylated DNA *in vitro* we performed electrophoretic mobility shift assays (EMSAs) using a recombinant N-terminal fragment of MeCP2 comprising amino-acids 1--205 (see Figure [1A](#F1){ref-type="fig"} for gel analysis of proteins used in this study). MeCP2\[1--205\] includes the entire MBD ([@B14]) and sequences corresponding to a region of chicken MeCP2 (amino-acids 72 to 196) shown by Strätling and colleagues to bind non-methylated GT-rich DNA sequences ([@B19],[@B20]) (Figure [1B](#F1){ref-type="fig"}). In comparative EMSAs, a non-methylated duplex probe containing GGTGT (Table [1](#tbl1){ref-type="table"}) bound to MeCP2\[1--205\] (Figure [1C](#F1){ref-type="fig"}). By this semi-quantitative assay, the binding affinity was comparable to that of a probe containing mCAC, but lower than the classical MeCP2 recognition sequence mCG (Figure [1D](#F1){ref-type="fig"}). Our results confirm that binding of chicken MBD to this non-methylated sequence *in vitro* is replicated with the human protein.

A previous study showed that the interaction of MeCP2 with mCAC, whose complement is GTG, depends on the cytosine methyl-group, but also on the methyl group provided by thymine. Binding was abolished by substitution of T, which is base-paired to the central adenine of CAC, by uracil (U), which lacks the 5′ methyl group ([@B8]). We asked whether thymine methyl groups in the GGTGT sequence were also necessary for binding. Synthetic probes in which both thymines (T) were substituted with U (oligo:GGUGU) showed strongly impaired binding (Figure [1E](#F1){ref-type="fig"}). Probes in which only the central thymine was substituted by U (oligo:GGUGT) showed a similar reduction, suggesting that this methyl group is essential for binding, whereas mutating the 3′ T to U (oligo:GGTGU) had only a marginal effect. Thus, the pyrimidine methyl group on the central thymine of the pentanucleotide motif is critical for cytosine methylation-independent binding by MeCP2.

As an N-terminal fragment of chicken MeCP2 can also bind to the sequence GTGTGT \[GT~3~\] ([@B20]), we used EMSAs to examine the effect of GT dinucleotide repeat length, from GT~1~ to GT~5~, on MeCP2\[1--205\] binding. Neither GT~1~ nor GTG (CAC on the complementary strand) bound significantly in EMSAs, but GT~2--5~ bound with similar affinity to GGTGT and mCAC, (Figure [2A](#F2){ref-type="fig"}). This suggests that GTGT is the minimal core MeCP2 target sequence *in vitro*. Alteration of bases at positions 1, 3 and 4 of this sequence showed that any deviation from GTGT greatly reduced binding by MeCP2\[1--205\] (Figure [2B](#F2){ref-type="fig"}). Background binding to CAC, base-paired with GTG, shows that the unmodified trinucleotide fails to interact by this assay (Figure [2A](#F2){ref-type="fig"}, [B](#F2){ref-type="fig"}, bottom panels). In addition, we found that probe sequences flanking GTGT had a strong effect on *in vitro* binding affinity, as simply inverting the GTGT motif within an otherwise unchanged probe diminished binding (Figure [2C](#F2){ref-type="fig"}). Also, as reported for chicken MeCP2 ([@B19]), replacing a neighbouring AT-rich sequence in the original probe by a more GC-rich sequence greatly reduced the interaction (Figure [2D](#F2){ref-type="fig"}). The results demonstrate that the complex formed between MeCP2\[1--205\] and GT-rich DNA is highly sensitive to the flanking DNA sequences.

![DNA sequence determinants of cytosine methylation-independent binding by MeCP2. (**A**) EMSAs using varying amounts of MeCP2\[1--205\] or no protein (−) with double-stranded oligonucleotide probes containing CAC, mCAC, GGTGT, GT~1~, GT~2~, GT~3~, GT~4~ or GT~5~ (see Table [1](#tbl1){ref-type="table"}) to assess the influence of GT-length on binding. Note that CAC is the complement of GTG, indicating that this trinucleotide motif does not bind MeCP2\[1--205\]. (**B**) EMSAs in which MeCP2\[1--205\] was incubated with oligonucleotide probes altered at either the first (XTGT), third (GTXT), or fourth (GTGX) positions in the presence of varying amounts of MeCP2\[1--205\] or no protein (−). Probes containing GT~1~ or GT~3~ were used as negative and positive controls, respectively. (**C**) Determination of the effect of DNA sequences flanking GTGT binding to MeCP2. EMSAs using varying amounts of MeCP2\[1--205\] or no protein (−) with probes containing GT~1~, GT~2~, GT~3~ or GT~2~-inv bot (GT~2~-inverted indicated by yellow highlighting and inverted arrow). (**D**) The effect of altering the base composition of the 3′-AT-flank adjacent to GTGT was assayed by EMSAs using varying amounts of MeCP2\[1--205\] or no protein (−) with probes containing GT~1~, GT~2~, GT~3~ or GT~2~-A/T mut in which the TT-, AA- and AA-dinucleotides 3′-adjacent to GTGT were substituted by CG (yellow highlight).](gkaa102fig2){#F2}

Cytosine methylation-independent DNA binding requires specific fragments of MeCP2 {#SEC3-2}
---------------------------------------------------------------------------------

GTGT binding, like mCG and mCAC binding, depends on a functional MBD, as mutation of the crucial arginine residue R111 to glycine abolished the interaction ((21) and data not shown). To determine more precisely whether the protein domains required for mCG binding and GGTGT binding are co-extensive we performed EMSAs using the minimal mCG-binding domain, MeCP2\[77--167\], whose structure in complex with methylated DNA was solved previously ([@B12]). MeCP2\[77--167\] bound to mCAC as expected, but the interaction with GGTGT was surprisingly reduced to near background levels (Figure [3A](#F3){ref-type="fig"}, [B](#F3){ref-type="fig"}). These data agree with the earlier finding that that protein sequences immediately C-terminal to the minimal MBD are required for MeCP2 to interact with DNA in a mC-independent fashion *in vitro* ([@B19]). We next examined the ability of full-length MeCP2 to bind probes containing GGTGT, CG and mCG. As reported previously, MeCP2\[1--486\] shows reduced discrimination between mCG and CG in EMSAs compared with shorter MBD-containing fragments, as non-specific DNA binding increases using this assay ([@B27]). Despite this limitation, we detected a reproducible preference for binding to mCG compared with CG (Figure [3C](#F3){ref-type="fig"}, [D](#F3){ref-type="fig"}). GGTGT-binding, however, was indistinguishable from that observed with non-methylated CG (Figure [3C](#F3){ref-type="fig"}, [D](#F3){ref-type="fig"}). Due to the high background in the EMSA assay, we adopted an alternative 'pull-down' assay whereby brain extracts were incubated with PCR-generated probes containing multiple CG, CAC, mCG, mCAC, GTGT or GGTGT motifs (see Table [1](#tbl1){ref-type="table"} for sequences) that were immobilised on beads ([@B23],[@B25]). Western blots detected strong retention of MeCP2 with mCG and mCAC, but no MeCP2 was recovered with CG, CAC, GTGT or GGTGT probes (Figure [3E](#F3){ref-type="fig"}). The results confirm that the affinity for GTGT seen with the MeCP2\[1--205\] sub-fragment *in vitro* is not a property shared by the intact protein.

![Cytosine methylation-independent binding requires specific fragments of MeCP2. (**A**) EMSA using varying amounts of MeCP2\[77--167\] or no protein (−) with probes containing non-methylated CG (CG), methylated mCG (mCG), methylated CAC (mCAC) or GGTGT. (**B**) Graph quantifying MeCP2\[77--167\] binding to probes containing CG (squares), mCG (circles), mCAC (triangles), or GGTGT (crosses). Mean percentage of probe shifted (±SEM) based on triplicate experiments. The results with the minimal MBD may be compared with those for MeCP2\[1--205\] in Figure [1C](#F1){ref-type="fig"} and [D](#F1){ref-type="fig"}. (**C**) Full-length MeCP2\[1--486\] has a diminished ability to bind GGTGT. EMSAs using varying amounts of MeCP2\[1--486\] or no protein (−) with probes containing non-methylated CG, methylated CG (mCG), or GGTGT. (**D**) Graph showing quantification of MeCP2\[1--486\] binding to probes containing mCG (filled circles), non-methylated CG (filled triangles), or GGTGT (filled squares). Mean percentage of probe shifted (±SEM) based on triplicate experiments. Statistical significance was measured between mCG and GGTGT: \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001 (unpaired two-tailed t-test). The results with full-length MeCP2 may be compared with those for MeCP2\[1--205\] in Figure [1C](#F1){ref-type="fig"} and [D](#F1){ref-type="fig"}. (**E**) Western blots with anti-MeCP2 antibody following DNA pull-down from rat brain nuclear extracts using immobilised DNA sequences containing CG, CAC, mCG, mCAC, GTGT, GGTGT. Left panel shows MeCP2 eluted from beads. Right panel shows that MeCP2 is present in all of the bead supernatants following pull-down. M = protein marker (Page-Ruler, Thermo Scientific).](gkaa102fig3){#F3}

MeCP2 does not detectably bind to GT-rich sequences *in vivo* {#SEC3-3}
-------------------------------------------------------------

The dependence of GT-motif binding on the surrounding DNA sequence context and on which domains of MeCP2 are tested made it critical to assess the relevance of this interaction *in vivo*. For this purpose, we interrogated MeCP2 ChIP-seq data derived from cultured human neurons (LUHMES cells) with varying levels of MeCP2 ([@B10]). These cells give rise to immature neurons with low levels of mCAC, which is advantageous when investigating MeCP2 binding to non-methylated CAC-containing motifs. A previous study showed enrichment of bound MeCP2 at mCG using ChIP-seq and also detected robust footprints at this methylated motif using ATAC-seq ([@B10]). We first searched the human reference genome for non-overlapping GTGT and GGTGT motifs with a 3′ run of A or T at least two base-pairs long within 13 bases and identified more than 10,000 examples of each (see Table [2](#tbl2){ref-type="table"}). Excluding the few regions with low read coverage in whole genome bisulfite sequencing (TAB-seq) data (coverage \< 10), motifs were then classified as either 'non-methylated' if no mC was detected within a 100 base-pair window surrounding the motif start position, or 'methylated' if \>10% of mC was present. The analysis yielded several thousand motifs of each kind (Table [2](#tbl2){ref-type="table"}).

###### 

Number of GT-rich motifs analysed. Methylated and non-methylated columns show the number of sequences that passed the thresholds applied for read coverage, methylation level **etc** (see Materials and Methods). The Total column refers to the total number of GT-rich sequences found in the reference genome

            Methylated motif   Non-methylated motif   Total
  --------- ------------------ ---------------------- ---------
  *GGTGT*   7131               6049                   153 588
  *GTGT*    7130               5485                   124 803

MeCP2-dependent ChIP enrichment at GT-rich motifs was tested by comparing MeCP2 ChIP-seq data from cells expressing wild-type levels of MeCP2, cells over-expressing MeCP2 at 11x the wild-type level, and cells in which the *MECP2* gene had been knocked-out (Figure [4A](#F4){ref-type="fig"}). A meta-analysis that plotted mean normalised ChIP-seq levels detected a peak of binding at both mCG and mCAC surrounded by a 100 base pair window that is otherwise non-methylated (Figure [4B](#F4){ref-type="fig"}). No peak of binding to non-methylated CG or CAC was present. A related analysis of GT-rich motifs lacking mC failed to detect MeCP2 binding in either WT or OE 11x cells. As a positive control, we found that GT-rich regions associated with one or more mCG or mCAC motifs within the surrounding 100 base pair window displayed a coincident MeCP2 ChIP peak (Figure [4C](#F4){ref-type="fig"}). A negative control was provided by the motifs GGGTTT and TTTGGG, which are not expected to bind MeCP2. They, like GT-rich motifs, failed to show ChIP peaks unless there was a methylated site nearby (Figure [4D](#F4){ref-type="fig"}). Summit analysis of ChIP peaks cannot be interpreted as a quantitative measure of binding, as we noted previously that peak height in ChIP-seq is not proportional to occupancy ([@B10]). Therefore, the variable peak heights associated with mCAC and GTGT when part of a methylated fragment do not imply differential affinities. Overall, the ChIP data offer no support for the notion that MeCP2 binds non-methylated GT-rich sequences *in vivo*.

![Native MeCP2 is not enriched at GT-rich sequences *in vivo*. (**A**) Western blot showing expression level of MeCP2 in WT, *MECP2* knockout (KO) and 11-fold over-expressing (OE 11x) human neuronal cells in culture (see reference ([@B10])). Replicates are independent cloned cell lines. (**B**) Composite plots showing log~2~ enrichment of MeCP2 over windows containing methylated or unmethylated CG (red broken or solid lines, respectively) and methylated or unmethylated CAC (blue broken or solid lines, respectively) that are otherwise free of methylation. (**C**) Composite plots showing log~2~ enrichment of MeCP2 over GTGT- containing (grey) and GGTGT-containing (black) windows that do (dashed lines) or do not (solid lines) contain cytosine methylation elsewhere. WT (left panel) and OE 11x (right panel) reads are normalised to KO. (**D**) Composite plots showing log~2~ enrichment of MeCP2 over windows containing GGGTTT (grey) and TTTGGG (black) that do (dashed lines) or do not (solid lines) contain cytosine methylation elsewhere. WT (left panel) and OE 11x (right panel) are normalised to KO.](gkaa102fig4){#F4}

We complemented MeCP2 ChIP-seq enrichment analysis with an independent assay that relies on ATAC-seq *in vivo* footprint analysis (Figure [5A](#F5){ref-type="fig"}). Here a consistent position of bound MeCP2 is essential for visualisation of the footprint, as variably dispersed binding sites would not be detected. To validate the method, we first calculated enrichment profiles over methylated and non-methylated CA in LUHMES cells overexpressing MeCP2 11-fold. We previously showed a clear footprint over mCG in this cell line ([@B10]). As expected, the MeCP2 footprint is also observed over methylated CA (Figure [5B](#F5){ref-type="fig"} left), but absent at non-methylated CA (Figure [5B](#F5){ref-type="fig"}, right). If the *in vivo* MeCP2 binding to GTGT was as strong as the *in vitro* MBD binding, we would therefore expect to see a footprint on GTGT-containing sequences. To check this, we looked for MeCP2 footprints on all GTGT and GGTGT sequences, irrespective of methylation, and used computer modelling to factor out contributions from mCG and mCA binding. Figure [5C](#F5){ref-type="fig"}, [D](#F5){ref-type="fig"} shows the absence of a footprint on GTGT and GGTGT in OE 11x LUHMES cells, in agreement with ChIP-seq *in vivo* data. Figure [5E](#F5){ref-type="fig"} shows the Bayesian posterior probability of MeCP2 binding GTGT with probability $\documentclass[12pt]{minimal}
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![Absence of an ATAC-seq footprint of MeCP2 at GT-rich sequences in native chromatin. (**A**) A schematic representation of the ATAC-seq procedure and footprint analysis. (**B**) ATAC-seq insertion profile shows a MeCP2 footprint over mCA (left) but no footprint over non-methylated CA (right). (**C**) and (**D**) Absence of footprint at GTGT (left) and GGTGT (right), respectively. (**E**) Bayesian posterior probability distribution (P\[x\]) of the GTGT binding probability versus GTGT binding strength relative to mCG binding (x) that best reproduces the experimental ATAC-seq insertion profile. For comparison P\[x\] for mCA is shown (dotted line).](gkaa102fig5){#F5}

DISCUSSION {#SEC4}
==========

We re-investigated early reports that MeCP2 binds non-methylated GT-rich DNA sequences *in vitro* ([@B19],[@B20]), which raised the possibility that GT-rich sequences are physiological ligands of MeCP2 ([@B21]). Our results confirmed that a sub-fragment of MeCP2 protein (MeCP2\[1--205\]) has a high affinity for the minimal target sequence GTGT. They also confirmed that binding depends upon a correctly orientated AT-rich flanking sequence and showed that a 5′ pyrimidine methyl group must be supplied by thymine. Unexpectedly we found that neither an isolated MBD polypeptide (MeCP2\[77--167\]) nor full-length MeCP2\[1--486\] supports the GT-rich mode of binding to a level above background *in vitro*. In apparent disagreement with this finding, a recent crystal structure of the minimal MBD complexed with a GTG(T)-containing DNA duplex has been determined ([@B21]). We note, however, that the dissociation constant reported for that interaction is 3--4 μM, which is an order of magnitude weaker than binding to mCG ([@B21],[@B28]) and close to the background affinity of the MeCP2 MBD for any DNA sequence ([@B28]). Presumably this weak interaction was favoured by the high concentrations of DNA and protein in the crystallisation liquor. Our evidence that the minimal MBD shows background binding to GTGT is consistent with the published report ([@B21]) that GTGT binding by the isolated MBD *in vitro* is much weaker than its affinity for mCG or mCAC.

We found that MeCP2\[1--205\] showed GTGT binding, but MeCP2\[77--167\] (the minimal MBD) bound this sequence very weakly. Previous work showed that the addition of seven amino acids C-terminal to the minimal MBD reduced mC-dependent DNA binding and increased non-specific interactions with DNA ([@B14]). The recent structure of the low affinity (∼4 μM) complex between CAC (which is the complement of GTG) and the minimal MBD ([@B21]) does not explain why the extra amino acids C-terminal should facilitate binding of the 1--205 fragment or why this effect is lost in the full-length protein. Previously published structures, which only involve domains corresponding to the minimal MBD (77--167), suggest that DNA binding is accompanied by subtle conformational changes which may influence this interaction, but do not provide information on interactions with the rest of the protein ([@B12],[@B29]). As our study revealed no evidence for GTGT binding to intact MeCP2, we do not consider that a detailed mechanistic understanding of this binding mode is a high priority.

Due to the inherent limitations of *in vitro* studies with purified components, we employed two independent *in vivo* assays to look for MeCP2 binding to GT-rich sequences *in vivo*. Using a human neuronal cell-line engineered to contain differing levels of MeCP2 we analysed ChIP-seq and ATAC-seq data ([@B10]). We verified that MeCP2 generates a ChIP peak and also a cytosine methylation-dependent footprint at the sequence mCAC, whose complement is GTG. Neither method of analysis detected evidence of MeCP2 binding to non-methylated GTGT or GGTGT motifs *in vivo*. In spite of this negative result, we cannot formally exclude the possibility that a subset of GT-rich sequences, below the detection limit of our assays, associates with MeCP2 *in vivo*. For example, changes to the sequence environment of GTGT may enhance binding. While we cannot disprove this possibility, several factors argue against it. Firstly, GGTGT is a subset of the simplest GTGT *in vitro* target sequence but tested negative for binding here. Secondly, for our *in vivo* analysis we imposed the condition that there must be a nearby AT-rich flanking sequence, as our evidence and the original work from the Strätling group ([@B19]) both indicated that a flanking AT-run aids *in vitro* binding by the MBD. Despite this attempt to enrich for favoured binding sites, we detected no MeCP2 footprints in native chromatin. Thirdly, we found that binding of full-length MeCP2 to this GT motif is indetectable using the sensitive pull-down assay for MeCP2 binding (Figure [3E](#F3){ref-type="fig"}). Thus, there is no *in vitro* precedent for an interaction of this kind involving the native protein *in vitro*. In the absence of experimental support for the notion that GT-rich sequences are physiological ligands of full-length MeCP2 *in vivo* or *in vitro*, the possibility that there is an undiscovered bound GT subset becomes highly speculative.

While these results affirm the importance of cytosine methylation for DNA binding by MeCP2, DNA sequence specificities other than GTGT have previously been considered. Recent reports suggested that GC-content rather than DNA methylation is the primary determinant of binding ([@B30]). As CpG islands are GC-rich but lack DNA methylation, this proposal conflicts with data from several laboratories showing that MeCP2 is depleted, not enriched, at these domains ([@B6],[@B8],[@B10],[@B25],[@B31]). It will be important to exclude the possibility that the intrinsic base compositional bias of DNA amplification and high throughput DNA sequencing contribute to this discrepancy. Two AT-hook motifs ([@B32]) contribute subtly to binding *in vivo* and *in vitro*, but appear to be dispensable, as polymorphisms that abolish the motifs occur in the population and mutations affecting them are absent in databases of clinically relevant mutations ([@B33]). In addition, to these known DNA binding domains, a non-specific affinity for DNA has been attributed to regions C-terminal to the NID ([@B32]). It is notable, however, that mice containing a radically truncated form of MeCP2 comprising only the MBD (a.a. 72--173) and NID (a.a. 272--312) are fully viable ([@B15]) suggesting that most of the protein, including the putative C-terminal DNA binding domain and AT-hooks, is non-essential.

As MeCP2 is a highly basic protein containing several disordered regions, it is important to distinguish non-specific DNA binding, for example due to electrostatic affinity to poly-anionic DNA, from those interactions that are specific and therefore more likely to be biologically relevant. This issue is illustrated by a chromatin immunoprecipitation study of mouse embryonic stem cells lacking DNA methylation, which found that MeCP2 binding redistributed to non-methylated sites in these cells ([@B17]). Mutations in the MBD that abolish or greatly reduce binding of MeCP2 to methylated DNA *in vitro* and *in vivo* nevertheless retained an association with chromatin. Despite persistence of chromatin binding, however, these mutant proteins cause Rett syndrome and are lethal in male mice. It follows that residual DNA methylation-independent binding cannot compensate for the absence of specific binding to methylated sites. Taken together, the data suggest that motifs containing 5-methylcytosine are the primary targets of MeCP2, predominantly in mCG and mCAC sites. Other modes of DNA binding, where confirmed, appear to be ancillary to this predominant DNA binding mode and consequently non-essential.

DATA AVAILABILITY {#SEC5}
=================

The data reported in this paper were deposited in the Gene Expression Omnibus (GEO) database, [www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo) (accession no. GSE125660).

We thank Matt Lyst and Jim Selfridge for comments on the manuscript and members of the Bird group, past and present, for constructive comments. We are also grateful to Professor Malcolm Walkinshaw for many discussions on the structure of MeCP2. In addition, we are indebted to Dr Stuart Cobb and his laboratory for supplying the rat brains used in this study.

FUNDING {#SEC6}
=======

Rett Syndrome Research Trust, a Wellcome Trust Centre \[091580/Z/10/Z\]; Wellcome Investigator Award \[107930/Z/15/Z\]; European Research Council Advanced \[EC 694295 Gen-Epix to A.B.\]; A.B. is a member of the Simons Initiative for the Developing Brain at the University of Edinburgh. Funding for open access charge: Wellcome Trust.

*Conflict of interest statement*. None declared.

[^1]: The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.
